BRI3 and breast carcinoma: Silencing of BRI3 expression clearly suppressed the phosphorylation of Erk, and consequently the proliferation and migration of MDA-MB-231 cells, suggesting that the BRI3-Erk signaling pathway is involved in regulation of this nifedipine effect on breast cancers.